Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Lood, Christian ^a   Tydén, Helena ^a   Gullstrand, Birgitta ^b   Sturfelt, Gunnar ^a   Jönsen, Andreas ^a   Truedsson, Lennart ^b   Bengtsson, Anders A ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4D; PADGEM PROTEIN; PHOSPHOLIPID ANTIBODY; CARDIOLIPIN; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; PEPTIDE FRAGMENT;

ADULT; AGED; ANTIGEN EXPRESSION; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT FIXATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; VEIN THROMBOSIS; ADOLESCENT; BLOOD; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; THROMBOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTIPHOSPHOLIPID; BLOOD PLATELETS; CARDIOLIPINS; COMPLEMENT ACTIVATION; COMPLEMENT C4B; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; RISK FACTORS; THROMBOSIS; YOUNG ADULT;

EID: 84903376271     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099386     Document Type: Article

References (44)

1. Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, et al. (2010) Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 16: 47-57.
2. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, et al. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44: 2331-2337. (Pubitemid 32977500)
3. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, et al. (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145: 408-415. (Pubitemid 27084212)
4. Jonsson H, Nived O, Sturfelt G (1989) Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 68: 141-150. (Pubitemid 19132411)
5. Rubin LA, Urowitz MB, Gladman DD (1985) Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 55: 87-98. (Pubitemid 15105095)
6. Al-Homood IA (2012) Thrombosis in systemic lupus erythematosus: a review article. ISRN Rheumatol 2012: 428269.
7. Koskenmies S, Vaarala O, Widen E, Kere J, Palosuo T, et al. (2004) The association of antibodies to cardiolipin, beta 2-glycoprotein I, prothrombin, and oxidized low-density lipoprotein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus. Scand J Rheumatol 33: 246-252. (Pubitemid 39180169)
8. Sallai KK, Nagy E, Bodo I, Mohl A, Gergely P (2007) Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol 36: 198-205. (Pubitemid 47174557)
9. Vikerfors A, Johansson AB, Gustafsson JT, Jonsen A, Leonard D, et al. (2013) Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford) 52: 501-509.
10. Betts NA, Ahuja KD, Adams MJ (2013) Anti-beta2GP1 antibodies have variable effects on platelet aggregation. Pathology 45: 155-161.
11. Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, et al. (2004) Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/ prothrombin antibodies - Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 91: 967-976. (Pubitemid 38647501)
12. Wiener HM, Vardinon N, Yust I (1991) Platelet antibody binding and spontaneous aggregation in 21 lupus anticoagulant patients. Vox Sang 61: 111-121.
13. Lin YL, Wang CT (1992) Activation of human platelets by the rabbit anticardiolipin antibodies. Blood 80: 3135-3143.
14. Wang L, Su CY, Chou KY, Wang CT (2002) Enhancement of human platelet activation by the combination of low concentrations of collagen and rabbit anticardiolipin antibodies. Br J Haematol 118: 1152-1162. (Pubitemid 35025984)
15. Vega-Ostertag M, Harris EN, Pierangeli SS (2004) Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 50: 2911-2919. (Pubitemid 39209530)
16. Pierangeli SS, Vega-Ostertag M, Liu X, Girardi G (2005) Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci 1051: 413-420. (Pubitemid 41362771)
17. Jönsson G, Sjöholm AG, Truedsson L, Bengtsson AA, Braconier JH, et al. (2007) Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency. Rheumatology (Oxford) 46: 1133-1139. (Pubitemid 47050617)
18. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, et al. (2003) Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112: 1644-1654. (Pubitemid 38063722)
19. Salmon JE, de Groot PG (2008) Pathogenic role of antiphospholipid antibodies. Lupus 17: 405-411. (Pubitemid 351798717)
20. Carrera-Marin A, Romay-Penabad Z, Papalardo E, Reyes-Maldonado E, Garcia-Latorre E, et al. (2012) C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies. Lupus 21: 1497-1505.
21. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, et al. (2002) Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 195: 211-220. (Pubitemid 34461265)
22. Navratil JS, Manzi S, Kao AH, Krishnaswami S, Liu CC, et al. (2006) Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 54: 670-674. (Pubitemid 43228646)
23. Lood C, Eriksson S, Gullstrand B, Jonsen A, Sturfelt G, et al. (2012) Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus - a possible link to venous thrombosis? Lupus 21: 1423-1432.
24. Peerschke E, Yin W, Alpert D, Roubey R, Salmon J, et al. (2009) Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus 18: 530-538.
25. Shinzato MM, Bueno C, Trindade Viana VS, Borba EF, Goncalves CR, et al. (2005) Complement-fixing activity of anticardiolipin antibodies in patients with and without thrombosis. Lupus 14: 953-958. (Pubitemid 43088269)
26. Hamad OA, Ekdahl KN, Nilsson PH, Andersson J, Magotti P, et al. (2008) Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 6: 1413-1421. (Pubitemid 352016323)
27. Mehta N, Uchino K, Fakhran S, Sattar MA, Branstetter BFt, et al. (2008) Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke 39: 3236-3241.
28. Kao AH, McBurney CA, Sattar A, Lertratanakul A, Wilson NL, et al. (2013) Relation of Platelet C4d with All-Cause Mortality and Ischemic Stroke in Patients with Systemic Lupus Erythematosus. Transl Stroke Res.
29. Testi R, Pulcinelli F, Frati L, Gazzaniga PP, Santoni A (1990) CD69 is expressed on platelets and mediates platelet activation and aggregation. J Exp Med 172: 701-707. (Pubitemid 20301216)
30. Testi R, Pulcinelli FM, Cifone MG, Botti D, Del Grosso E, et al. (1992) Preferential involvement of a phospholipase A2-dependent pathway in CD69-mediated platelet activation. J Immunol 148: 2867-2871.
31. Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29: 288-291. (Pubitemid 34118775)
32. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277. (Pubitemid 13221242)
33. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, et al. (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39: 363-369. (Pubitemid 26085211)
34. Hughes G (2007) Hughes Syndrome: the antiphospholipid syndrome - a clinical overview. Clin Rev Allergy Immunol 32: 3-12.
35. Hughes GR, Khamashta MA (1994) The antiphospholipid syndrome. J R Coll Physicians Lond 28: 301-304. (Pubitemid 24247517)
36. Tsubakio T, Tani P, Curd JG, McMillan R (1986) Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura. Br J Haematol 63: 293-300. (Pubitemid 16085862)
37. Ziakas PD, Routsias JG, Giannouli S, Tasidou A, Tzioufas AG, et al. (2006) Suspects in the tale of lupus-associated thrombocytopenia. Clin Exp Immunol 145: 71-80. (Pubitemid 43893935)
38. Anderson GP, van de Winkel JG, Anderson CL (1991) Anti-GPIIb/IIIa (CD41) monoclonal antibody-induced platelet activation requires Fc receptor-dependent cell-cell interaction. Br J Haematol 79: 75-83.
39. Lood C, Amisten S, Gullstrand B, Jönsen A, Allhorn M, et al. (2010) Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 116: 1951-1957.
40. Larsson A, Egberg N, Lindahl TL (1994) Platelet Activation and Binding of Complement Components to Platelets Induced by Immune-Complexes. Platelets 5: 149-155. (Pubitemid 24168276)
41. Shanmugavelayudam SK, Rubenstein DA, Yin W (2011) Effects of physiologically relevant dynamic shear stress on platelet complement activation. Platelets.
42. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, et al. (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104: 1887-1893. (Pubitemid 32983229)
43. Wraith KS, Magwenzi S, Aburima A, Wen Y, Leake D, et al. (2013) Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase-signaling pathways. Blood 122: 580-589.
44. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, et al. (2010) Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327: 580-583.